This document summarizes a 106-page report on the pipeline of therapeutics under development for acute renal failure (ARF)/acute kidney injury. The report provides an overview of the therapeutic pipeline as of the second half of 2012, including details on late-stage, mid-clinical stage, early clinical stage, and pre-clinical products. It reviews key players and universities involved in developing treatments for ARF/acute kidney injury and allows identification of emerging companies. The report can be purchased for various license fees or a sample may be requested.

1. You can also request for sample page of above
mention reports on sample@aarkstore.com

2. Pages : 106
PDF - $ 2000 | Site Licence - $ 4000 $ | Enterprise License - $
6000 |

3. Summary
Global Markets Direct’s, Acute Renal Failure (ARF) (Acute Kidney Injury) -
Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic
pipeline. This report provides information on the therapeutic development for
Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates,
and special features on late-stage and discontinued projects. It also reviews key
players involved in the therapeutic development for Acute Renal Failure (ARF)
(Acute Kidney Injury). Acute Renal Failure (ARF) (Acute Kidney Injury) -
Pipeline Review, Half Year is built using data and information sourced from
Global Markets Direct’s proprietary databases, Company/University websites,
SEC filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources, put together
by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.

4. Scope
- A snapshot of the global therapeutic scenario for Acute Renal Failure (ARF) (Acute
Kidney Injury).
- A review of the Acute Renal Failure (ARF) (Acute Kidney Injury) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under
development for Acute Renal Failure (ARF) (Acute Kidney Injury).
- Identify emerging players with potentially strong product portfolio and design
effective counter-strategies to gain competitive advantage.

5. Table of Contents :
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Acute Renal Failure (ARF) (Acute
Kidney Injury) 11
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under
Development by Companies 13
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under
Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Pre-Clinical Stage Products 21
Comparative Analysis 21……………..

6. Please follow link if you want More Related
Reports :
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?searc
h=Pipeline Review, H2 2012&PubId=&pagenum=1

7. Related Reports:
Wounds – Pipeline Review, H2 2012
Gallbladder Cancer – Pipeline Review, H2 2012
Sickle Cell Disease – Pipeline Review, H2 2012
Traumatic Brain Injury – Pipeline Review, H2 2012
Male Sexual Dysfunction – Pipeline Review, H2 2012
Waldenstrom Macroglobulinemia – Pipeline Review, H2 2012
AIDS - Related Cancer – Pipeline Review, H2 2012
Cutaneous T-Cell Lymphoma – Pipeline Review, H2 2012
Diabetic Macular Edema – Pipeline Review, H2 2012
Osteosarcoma – Pipeline Review, H2 2012
Mild Cognitive Impairment – Pipeline Review, H2 2012
Plasma Cell Neoplasm – Pipeline Review, H2 2012
Pulmonary Arterial Hypertension – Pipeline Review, H2 2012
Systemic Sclerosis (Scleroderma) – Pipeline Review, H2 2012
Burkitt Lymphoma – Pipeline Review, H2 2012
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic
Purpura) – Pipeline Review, H2 2012

8. For More details about above & other
Reports plz contact :
Lavanya
Aarkstore.com
Contact: Marketing team Mob.No.918149852585
Email: enquiry@aarkstore.com ,
discount@aarkstore.com
URL: http://www.aarkstore.com
http://in.linkedin.com/in/aarkstore
http://www.facebook.com/aarkstore